Three law firms and a consultancy are fighting a bid by defunct financial advisor Dover Financial to bring negligence claims against two lawyers over a so-called client protection policy found to be “an exercise in Orwellian doublespeak”.
Drug company Ono Pharmaceutical has faced tough questioning by an appeals court in a fight with IP Australia over a decision that secured it a patent extension for its cancer immunotherapy drug Opdivo.
US-based facial recognition software company Clearview AI has been ordered to cease collecting facial images from individuals in Australia and destroy all the data it has collected within the country.
E&P Financial Group says it will defend a class action brought against it, subsidiary Dixon Advisory and director Alan Dixon, alleging they reaped millions of dollars in fees by pushing unsuitable financial products onto investors.
A judge has declined to quash the indictment in a high-profile criminal case over a $2.5 billion ANZ share placement but sent prosecutors back to the drawing board to remedy its defects, calling the state of affairs “a complete shemozzle”.
JPMorgan’s general counsel for Australia and New Zealand was allowed to sit in on witness interviews during an ACCC cartel investigation into ANZ’s $2.5 billion share placement despite allegedly being involved in the cartel conduct, a judge has heard.
A judge has rejected part of IVF provider Virtus Health’s bid for redactions in a recent decision from the court temporarily blocking the company from purchasing rival Adora Fertility, saying some of the confidentiality claims were “staggering” and “border on ridiculous.”
The High Court has found a 15 per cent ‘backpacker tax’ imposed on holders of Australian working holiday visas violates a double taxation agreement between Australia and the UK.
A judge has ordered a class action against AMP to provide more detail in its case accusing the financial services firm of failing to disclose information to shareholders about allegedly misleading ASIC and charging clients fees for no service.
The Australian Securities and Investments Commission has accused Finnish microloan company Ferratum of overcharging vulnerable, low-income consumers during the height of the COVID-19 pandemic.